In details, these subcohorts consisted of 133 and 92 samples from primary tumor sites of patients treated with nivolumab (pN, anti-PD-1) or everolimus (pE, mammalian target of rapamycin [mTOR] inhibitor), respectively, and 47 and 37 samples from tumor metastases of patients treated with nivolumab (mN, anti PD-1) or everolimus (mE, mTOR inhibitor), respectively (Table S1). Here, MTOR is linked to neoplasm.